TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA

被引：0
|
作者：
van Beurden-Tan, C. [1 ]
Forero, J. [2 ]
Coggia, A. [1 ]
Bustos Marquez, M. C. [2 ]
机构：
[1] Amgen Inc, Rotkreuz, Switzerland
[2] Amgen Inc, Bogota, Colombia
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN225
引用
收藏
页码：S480 / S480
页数：1
相关论文
共 50 条
  • [31] Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation
    Martin, Thomas G.
    Capra, Marcelo
    Mohty, Mohamad
    Suzuki, Kenshi
    Quach, Hang
    Cavo, Michele
    Moreau, Philippe
    Dimopoulos, Meletios
    Yong, Kwee
    Tekle, Christina
    Foster, Meredith C.
    Barnes, Yvonne
    Risse, Marie-Laure
    Mikhael, Joseph
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (02): : 134.e1 - 134.e7
  • [32] Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
    Stewart, A. Keith
    Rajkumar, S. Vincent
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David S.
    Mihaylov, Georgi G.
    Goranova-Marinova, Vesselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    San-Miguel, Jesus F.
    Ludwig, Heinz
    Wang, Michael
    Maisnar, Vladimr
    Minarik, Jiri
    Bensinger, William I.
    Mateos, Maria-Victoria
    Ben-Yehuda, Dina
    Kukreti, Vishal
    Zojwalla, Naseem
    Tonda, Margaret E.
    Yang, Xinqun
    Xing, Biao
    Moreau, Philippe
    Palumbo, Antonio
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02) : 142 - 152
  • [33] Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis
    Capra, Marcelo
    Martin, Thomas, III
    Moreau, Philippe
    Baker, Ross
    Pour, Ludek
    Min, Chang-Ki
    Leleu, Xavier
    Mohty, Mohamad
    Segura, Marta Reinoso
    Turgut, Mehmet
    Leblanc, Richard
    Risse, Marie-Laure
    Malinge, Laure
    Schwab, Sandrine
    Dimopoulos, Meletios A.
    BLOOD, 2020, 136
  • [34] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
    Facon, Thierry
    Moreau, Philippe
    Martin, Thomas G.
    Spicka, Ivan
    Oriol, Albert
    Koh, Youngil
    Lim, Andrew
    Mikala, Gabor
    Rosinol, Laura
    Yagci, Munci
    Cavo, Michele
    Yong, Kwee
    Risse, Marie-Laure
    Asset, Gaelle
    Schwab, Sandrine
    Martinez, Gracia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
    Capra, Marcelo
    Martin, Thomas
    Moreau, Philippe
    Baker, Ross
    Pour, Ludek
    Min, Chang-Ki
    Leleu, Xavier
    Mohty, Mohamad
    Reinoso Segura, Marta
    Turgut, Mehmet
    LeBlanc, Richard
    Risse, Marie-Laure
    Malinge, Laure
    Schwab, Sandrine
    Dimopoulos, Meletios
    HAEMATOLOGICA, 2022, 107 (06) : 1397 - 1409
  • [36] Updated Results from a Matching-Adjusted Indirect Comparison of Efficacy Outcomes of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
    Richter, Joshua
    Lin, Peggy L.
    Garcia-Horton, Viviana
    Guyot, Patricia
    Zhou, Zheng-Yi
    Sievert, Mark
    BLOOD, 2023, 142
  • [37] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Munshi, Nikhil C.
    Mitsiades, Constantine
    Richardson, Paul G.
    Anderson, Kenneth C.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 374 - 375
  • [38] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
    Iida, Shinsuke
    Chou, Takaaki
    Okamoto, Shinichiro
    Nagai, Hirokazu
    Hatake, Kiyohiko
    Murakami, Hirokazu
    Takagi, Toshiyuki
    Shimizu, Kazuyuki
    Lau, Henry
    Takeshita, Kenichi
    Takatoku, Masaaki
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 118 - 126
  • [39] Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma
    不详
    FORMULARY, 2008, 43 (02) : 79 - 80
  • [40] Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
    Nikhil C Munshi
    Constantine Mitsiades
    Paul G Richardson
    Kenneth C Anderson
    Nature Clinical Practice Oncology, 2008, 5 : 374 - 375
12345